Therapeutic polymer gel system to promote healing and prevent fibrosis at a wound or surgical site
US-2020085859-A1 · Mar 19, 2020 · US
US10912860B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10912860-B2 |
| Application number | US-201715701113-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 11, 2017 |
| Priority date | Jul 17, 2014 |
| Publication date | Feb 9, 2021 |
| Grant date | Feb 9, 2021 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A microporous gel system for certain applications, including biomedical applications, includes an aqueous solution containing plurality of microgel particles including a biodegradable crosslinker. In some aspects, the microgel particles act as gel building blocks that anneal to one another to form a covalently-stabilized scaffold of microgel particles having interstitial spaces therein. In certain aspects, annealing of the microgel particles occurs after exposure to an annealing agent that is endogenously present or exogenously added. In some embodiments, annealing of the microgel particles requires the presence of an initiator such as exposure to light. In particular embodiments, the chemical and physical properties of the gel building blocks can be controlled to allow downstream control of the resulting assembled scaffold. In one or more embodiments, cells are able to quickly infiltrate the interstitial spaces of the assembled scaffold.
Opening claim text (preview).
What is claimed is: 1. A method of delivering to living mammalian tissue a covalently-stabilized porous scaffold of spherical microgel particles comprising: (a) delivering to the living mammalian tissue a plurality of flowable, spherical microgel particles comprising diameters between 10 micrometers to 1000 micrometers, the plurality of flowable, spherical microgel particles comprising a cross-linked poly(ethylene glycol) (PEG) backbone polymer cross-linked with a matrix metalloprotease (MMP)-degradable crosslinker and an annealing component comprising K-peptides and Q-peptides and a cell-adhesive peptide comprising RGD; and (b) following delivery in (a) exposing the flowable, spherical microgel particles to an annealing agent comprising Factor XIIIa that links the flowable, spherical microgel particles together via a covalent annealing reaction at points of physical contact between adjacent spherical microgel particles via the K peptides and Q-peptides to form the covalently-stabilized porous scaffold, wherein the covalently-stabilized porous scaffold comprises pores with a median diameter of about 10 to about 35 micrometers into which cells from the living mammalian tissue become integrated within forty-eight hours of exposing in (b).
Hydrogels or hydrocolloids · CPC title
Materials at least partially resorbable by the body · CPC title
obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds · CPC title
Materials resorbable by the body · CPC title
the modifying agent being a protein, peptide or polyamino acid · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.